Why Jazz Pharmaceuticals Is an Attractive Buyout Candidate

Despite a high volume of European acquisitions Jazz Pharmaceuticals is yet to join the party, but why not, and will it ever?

Jun 18, 2014 at 9:41AM

A tax inversion plan among large U.S. companies has grown evident as they attempt to find lower tax rates and higher profits via relocation into various countries within Europe. Already, Elan, AstraZeneca plc, Alliance Boots, and now Covidien plc have either been attempted or successfully acquired. Yet, the most surprising might be a lack of action surrounding Jazz Pharmaceuticals plc (NASDAQ:JAZZ) -- Why is this biotech being avoided?

The offers come rolling in
AstraZeneca shares have soared 25% this year. These gains were tied directly to Pfizer's failed bid for the company..

AstraZeneca surprisingly rejected the offer despite stagnant growth and concerns of an impending Crestor patent expiration. England's 21% corporate tax rate, which compares favorably to the U.S. tax rate of 35%, was a key driver behind Pfizer's attempt to buy Astra.

However, if you thought a 21% tax rate was good, then check out Ireland where the corporate tax rate is only 12.5%. Over the last weekend news hit of a $40 billion Covidien takeover offer, making it another large attempt at a European company. Unlike AstraZeneca, Covidien does have some anticipated growth, as revenue is expected by analysts to increase in the low-to-mid single digits over the next couple of years.

AstraZeneca and Covidien are two extremely large companies to receive buyout offers, showing a sense of urgency on behalf of large U.S. companies to relocate.

Another opportunity?
Looking at the acquisitions and those already attempted we can clearly see where the greatest risks lie, and also assume that the companies with the most value have already received a bid or have been acquired. This certainly brings up the question of Jazz Pharmaceuticals, an Ireland-based biotech.

Jazz markets about a dozen products across a variety of industries with annual revenue of $923 million, and analysts are estimating revenue growth of 30% and 20%, respectively, in 2014 and 2015. With a market capitalization of $8.4 billion it would seem the tax benefit alone would be enough to attract a larger pharma company, yet still no offers.

For 2014 Jazz expects revenue of $1.13 billion with its narcolepsy drug Xyrem accounting for around $765 million of that. Its top three drugs are expected to account for nearly 90% of total sales, meaning its remaining drugs have little impact fundamentally.

Why avoid Jazz?
So why would a company looking to lower its tax rate avoid Jazz Pharmaceuticals? The most obvious reason is potential competition to Xyrem both generic and from pipeline development. So far no generics have been approved, and Jazz now has a phase 3-ready candidate called JZP-110 that produced solid clinical results in treating narcolepsy. The drug performed well in a phase 2b trial, giving Jazz additional opportunities in the narcolepsy space even if generics eventually attack Xyrem.

The other concern revolves around Jazz's $1 billion purchase of Gentium. With this acquisition Jazz gained Defibrotide, a drug that treats an orphan disease called veno occlusive disease that's expected to generate $50 million in sales this year. The hope is that Defibrotide proves successful in treating larger indications such as Graft-vs-Host disease and multiple myeloma. If so, sales could eventually reach $500 million, but Jazz needs a lot of data to fall in its favor.

With that said, if Jazz were to lose patent protection on Xyrem or if the Gentium acquisition turns out to be a flop then the company would appear significantly overvalued. While its pipeline is not the largest, Jazz does have a number of intriguing assets like JZP-110 that could hopefully help counter any potential revenue losses.

Foolish Thoughts
I like Jazz's pipeline, and I think it's got some exciting growth opportunities over the next few years. It's hard to imagine that Jazz isn't on someone's radar given the big potential benefits of revenue growth and a potential tax inversion in Ireland. Nonetheless, as many investors learned earlier this year, it's important to invest in a company based on its growth drivers and not takeover speculation. I would encourage biotech-savvy investors to dig deeper into Jazz, and stay tuned for more news -- maybe health care's buyout bonanza isn't done yet!

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Brian Nichols owns shares of Jazz Pharmaceuticals. The Motley Fool recommends Covidien. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information